Manufacturer record

Caremax Formulations: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

4 batches manufactured by Caremax Formulations (Himachal Pradesh) were declared Not of Standard Quality between October 2019 and October 2021. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

4 records linked to Caremax Formulations in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
4Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Oct 2019 to Oct 2021

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

4
NSQ batches since 2019
4
Products affected
Dissolution
Most common failure
Oct 2021
Latest alert

Flagged batches per year

2019 · 12021 · 3

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Diclofenac Sodium Tablets IP (DECIFEN-50 TABLETS CLT-14750Mfg 2020-03 · Exp 2023-02 Disintegration TestDisintegration RDTL ChandigarhCDSCO lab Oct 2021
Paracetamol Tablets IP (CAREMOL TABLETS) CLT-14398Mfg 2019-12 · Exp 2022-11 DissolutionDissolution RDTL ChandigarhCDSCO lab Sep 2021
TELMISARTAN TABLETS IP 40 MG CLT-14747Mfg 2020-03 · Exp 2022-02 Uniformity of weight & DissolutionDissolution RDTL ChandigarhCDSCO lab Apr 2021
Amikacin Sulphate Injection IP (AMIKACARE 500 ) CLI-6868Mfg 2018-11 · Exp 2020-10 Particulate MatterParticulate matter RDTL ChandigarhCDSCO lab Oct 2019

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.